These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 25400215)

  • 1. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.
    González-López TJ; Pascual C; Álvarez-Román MT; Fernández-Fuertes F; Sánchez-González B; Caparrós I; Jarque I; Mingot-Castellano ME; Hernández-Rivas JA; Martín-Salces M; Solán L; Beneit P; Jiménez R; Bernat S; Andrade MM; Cortés M; Cortti MJ; Pérez-Crespo S; Gómez-Núñez M; Olivera PE; Pérez-Rus G; Martínez-Robles V; Alonso R; Fernández-Rodríguez A; Arratibel MC; Perera M; Fernández-Miñano C; Fuertes-Palacio MA; Vázquez-Paganini JA; Gutierrez-Jomarrón I; Valcarce I; de Cabo E; Sainz A; Fisac R; Aguilar C; Paz Martínez-Badas M; Peñarrubia MJ; Calbacho M; de Cos C; González-Silva M; Coria E; Alonso A; Casaus A; Luaña A; Galán P; Fernández-Canal C; Garcia-Frade J; González-Porras JR
    Am J Hematol; 2015 Mar; 90(3):E40-3. PubMed ID: 25400215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia.
    González-López TJ; Sánchez-González B; Pascual C; Arefi M; de Cabo E; Alonso A; Martín-Salces M; Jiménez-Bárcenas R; Calbacho M; Galan P; Barez A; González-Porras JR
    Platelets; 2015; 26(1):83-6. PubMed ID: 24499036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
    González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
    Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
    Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
    Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
    N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.
    Iino M; Sakamoto Y; Sato T
    Int J Hematol; 2020 Aug; 112(2):159-168. PubMed ID: 32476083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.
    Maroun MC; Ososki R; Andersen JC; Dhar JP
    Lupus; 2015 Jun; 24(7):746-50. PubMed ID: 25416695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
    González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Jarque I; Pérez-Rus G; Pérez-Crespo S; Bernat S; Hernández-Rivas JA; Andrade MM; Cortés M; Gómez-Nuñez M; Olivera P; Martínez-Robles V; Fernández-Rodríguez A; Fuertes-Palacio MA; Fernández-Miñano C; de Cabo E; Fisac R; Aguilar C; Bárez A; Peñarrubia MJ; García-Frade LJ; González-Porras JR
    Eur J Haematol; 2016 Sep; 97(3):297-302. PubMed ID: 26709028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond.
    Taylor A; Westwood JP; Laskou F; McGuckin S; Scully M
    Br J Haematol; 2017 May; 177(3):475-480. PubMed ID: 28295201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
    González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Pérez-Rus G; Hernández-Rivas JA; Bernat S; Bastida JM; Martínez-Badas MP; Martínez-Robles V; Soto I; Olivera P; Bolaños E; Alonso R; Entrena L; Gómez-Nuñez M; Alonso A; Yera Cobo M; Caparrós I; Tenorio M; Arrieta-Cerdán E; Lopez-Ansoar E; García-Frade J; González-Porras JR
    Br J Haematol; 2017 Sep; 178(6):959-970. PubMed ID: 28573819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP).
    Bussel JB; Saleh MN; Vasey SY; Mayer B; Arning M; Stone NL
    Br J Haematol; 2013 Feb; 160(4):538-46. PubMed ID: 23278590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a role for low-dose eltrombopag as maintenance therapy in the treatment of immune thrombocytopenia?
    Vlachaki E; Sousos N; Perifanis V; Kaiafa G; Onoufriadis I; Hatzitolios A; Boura P
    Acta Haematol; 2015; 133(1):78-82. PubMed ID: 25170628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
    Tarantino MD; Fogarty PF; Shah P; Brainsky A
    Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of eltrombopag in treatment-refractory primary immune thrombocytopenia: a retrospective study.
    Eser A; Toptas T; Kara O; Sezgin A; Noyan-Atalay F; Yilmaz G; Ozgumus T; Pepedil-Tanrikulu F; Kaygusuz-Atagunduz I; Firatli-Tuglular T
    Blood Coagul Fibrinolysis; 2016 Jan; 27(1):47-52. PubMed ID: 26258668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia.
    Tomiyama Y; Miyakawa Y; Okamoto S; Katsutani S; Kimura A; Okoshi Y; Ninomiya H; Kosugi H; Nomura S; Ozaki K; Ikeda Y; Hattori T; Katsura K; Kanakura Y
    J Thromb Haemost; 2012 May; 10(5):799-806. PubMed ID: 22409309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.